Novartis Withdraws Prexige In Australia Ahead Of FDA Decision Due To Deaths
This article was originally published in The Pink Sheet Daily
Executive Summary
Withdrawal of the COX-2 inhibitor in Australia following two deaths from liver injury is likely to impact the outcome of FDA’s review.